Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3962673 · 1 trial · 3 indications
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
BOR per investigator assessed RECIST 1.1
DOR per investigator assessed RECIST 1.1
TTR per investigator assessed RECIST 1.1
DCR per investigator assessed RECIST 1.1
| Arm | Type | Description |
|---|---|---|
| Phase 1a: LY3962673 Dose Escalation | EXPERIMENTAL | Escalating doses of LY3962673 administered orally. |
| Phase 1b: LY3962673 Dose Expansion | EXPERIMENTAL | LY3962673 administered orally either alone or in combination with other chemotherapy agents. |
| Experimental: Phase 1a: LY3962673 Monotherapy | EXPERIMENTAL | LY3962673 administered orally |
| Name | Type | Description |
|---|---|---|
| LY3962673 | DRUG | Administered orally. |
| Cetuximab | DRUG | Administered intravenously. |
| Gemcitabine | DRUG | Administered intravenously. |
| nab-paclitaxel | DRUG | Administered intravenously. |
| Oxaliplatin | DRUG | Administered intravenously. |
| leucovorin | DRUG | Administered intravenously. |
| Irinotecan | DRUG | Administered intravenously. |
| 5-fluorouracil | DRUG | Administered intravenously. |
Inclusion Criteria: * Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Have evidence of KRAS G12D mutation in tumor tissue or circulating tu...
LY3962673 is an investigational small molecule being studied for the treatment of Pancreatic Ductal Adenocarcinoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being evaluated in patients with KRAS G12D-mutant solid tumors, including pancreatic cancer.
LY3962673 targets KRAS G12D, a mutated form of the KRAS oncogene. By targeting this specific mutation, the drug aims to interfere with cancer cell growth and survival. This makes it a potential precision therapy for tumors harboring the KRAS G12D mutation.
LY3962673 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with KRAS G12D-mutant solid tumors.
LY3962673 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval for commercial use. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and preliminary efficacy in patients with KRAS G12D-mutant solid tumors.
LY3962673 is being studied in the MOONRAY-01 trial (NCT06586515), a Phase 1 study in participants with KRAS G12D-mutant solid tumors. The trial is recruiting patients with Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, and Colorectal Cancer across multiple countries, including the United States, Canada, China, and several European and Asian nations.
No alternative names for LY3962673 have been reported. The drug is identified solely by its investigational code LY3962673 in clinical trial registries and scientific literature. It is a distinct small molecule being developed by Eli Lilly and Company for the treatment of KRAS G12D-mutant cancers.